mart-1-antigen and Sex-Cord-Gonadal-Stromal-Tumors

Topics: 12E7 Antigen; Antigens, CD; Calbindin 2; Carcinoma, Endometrioid; CD56 Antigen; Cell Adhesion Molecules; Cystadenocarcinoma, Serous; Diagnosis, Differential; Female; Humans; Immunohistochemistry; Inhibins; MART-1 Antigen; Neprilysin; Ovarian Neoplasms; S100 Calcium Binding Protein G; Sertoli-Leydig Cell Tumor; Sex Cord-Gonadal Stromal Tumors; Steroidogenic Factor 1; WT1 Proteins

Fourteen steroid cell tumors (SCTs) of the ovary were studied by immunohistochemistry including inhibin, calretinin, CD99, Melan A, androgen receptor, and AE1/3. Twelve tumors were primary and 2 were recurrent. The primary tumors included 5 stromal luteomas (SL), 5 SCTs, not otherwise specified, and 2 Leydig cell tumors, 1 of the hilar type and 1 of the nonhilar type. All tumors were classified according to the predominant cell type. Six tumors were eosinophilic cell type, 3 clear-cell type, and 5 were mixed eosinophilic-clear-cell type. Inhibin, calretinin, and CD99 were positive in all 14 tumors. Twelve of 14 tumors (86%) were positive for Melan A and 9 of 14 (64%) for androgen receptor. AE 1/3 immunopositivity was found in 5 of 14 tumors (36%). Immunohistochemistry helps in the distinction between SCTs of the ovary and other primary or metastatic ovarian neoplasms with eosinophilic and clear-cell histology. In addition, immunohistochemistry can confirm the presence of recurrent SCT, if no sufficient clinical history is provided. As some SCTs can be positive for epithelial markers and histologically similar epithelial tumors can be positive for sex cord stromal markers, the use of multiple immunohistochemical stains is recommended.

Topics: 12E7 Antigen; Adult; Aged; Aged, 80 and over; Antigens, CD; Antigens, Neoplasm; Calbindin 2; Cell Adhesion Molecules; Female; Humans; Immunohistochemistry; Inhibins; MART-1 Antigen; Middle Aged; Neoplasm Proteins; Ovarian Neoplasms; Receptors, Androgen; S100 Calcium Binding Protein G; Sex Cord-Gonadal Stromal Tumors

In this study, we present the clinicopathologic features and immunophenotypic characteristics of five cases of uterine tumors resembling ovarian sex cord tumors and three cases of endometrial stromal tumors with sex cord-like elements, with emphasis on immunohistochemical markers of sex cord differentiation. The mean patient age was 42 years (range 19-69 years), and vaginal bleeding was the most common clinical presentation. The tumors were usually polypoid masses arising in the uterine fundus, with a mean tumor size of 6.7 cm. Sex cord patterns in uterine tumors resembling ovarian sex cord tumors, including anastomosing cords, trabeculae, small nests, tubules, and in one case, a striking retiform architecture with Leydig-like cells, comprised from 70 to 100% of the tumor volume. All uterine tumors resembling ovarian sex cord tumors were positive for two or more markers of sex cord differentiation; all five cases showed strong immunoreactivity for calretinin, with coexpression of CD99 (four cases), Melan-A (two cases), and inhibin (two cases). Endometrial stromal tumors with sex cord-like elements were less frequently positive for markers of sex cord differentiation, with each case positive for one marker (calretinin, two cases; CD99, one case). In addition, all eight cases were frequently positive for cytokeratin, CD10, vimentin, estrogen receptor, and progesterone receptor; desmin immunoreactivity, when present, was limited to minor foci of smooth muscle. Overall, the morphologic and immunohistochemical findings in uterine tumors resembling ovarian sex cord tumors strongly support that these unusual uterine tumors are polyphenotypic neoplasms with true sex cord differentiation.

Topics: 12E7 Antigen; Adult; Aged; Antigens, CD; Antigens, Neoplasm; Biomarkers; Calbindin 2; Cell Adhesion Molecules; Cell Differentiation; Female; Follow-Up Studies; Humans; Immunohistochemistry; Inhibins; Keratins; MART-1 Antigen; Middle Aged; Neoplasm Proteins; Neprilysin; Ovarian Neoplasms; Receptors, Estrogen; Receptors, Progesterone; S100 Calcium Binding Protein G; Sex Cord-Gonadal Stromal Tumors; Uterine Neoplasms; Vimentin